首页> 美国卫生研究院文献>Cytotechnology >Topoisomerase I inhibitors and drug resistance
【2h】

Topoisomerase I inhibitors and drug resistance

机译:拓扑异构酶I抑制剂和耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing the phenomenon. This article describes the role of topoisomerase I in cell functions and the methods used to assess its in vitro catalytic activity. It reviews the mechanisms of cytotoxicity of the most specific antitopoisomerase I drugs by considering also the phenomenon of drug resistance. Some factors useful to drive the future perspectives in the development of new topoisomerase I inhibitors are also evidenced and discussed.
机译:DNA拓扑异构酶I是一种核酶,它通过将单链断裂引入DNA分子来催化DNA拓扑的转换。该酶代表了属于喜树碱抗肿瘤药系列的抗拓扑异构酶药物在癌症治疗中的新颖独特分子靶标。由于许多肿瘤都能获得对药物治疗的抗药性并对化疗变得难治,因此研究这种抗药性所涉及的机制来规避该现象非常重要。本文介绍了拓扑异构酶I在细胞功能中的作用以及用于评估其体外催化活性的方法。它通过考虑耐药性现象来回顾最具体的抗拓扑异构酶I药物的细胞毒性机制。还证明和讨论了一些因素,这些因素可推动新型拓扑异构酶I抑制剂的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号